In contrast, it is also possible to envision a scenario in which the reduced serum levels of ghrelin in CRC patients are a secondary occurrence, resulting from the inhibitory effect of other tumour progression-associated factors/hormones on its production [142]. The gene discussed is GHRL; the disease is neoplasm.